News and Announcements
Alcidion Group Commercialises Miya Platform Throughout Australia & New Zealand & Secures $2.35m Contract with Western Health
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Alcidion Group Limited (ASX:ALC) is pleased to provide a summary of its progress over the quarter ending 30 June 2017 and report on its cashflow over the same period.
KEY TAKEAWAYS:
- Significant milestones achieved in commercialising the Miya platform throughout Australia and New Zealand.
- Securing of a $AUD2.35m Contract with Western Health, crystallising a long term relationship with Western Health.
- Securing a $NZD1.60m Contract with Mid Central, the Company’s first deployment in New Zealand, paving the way for future engagement with the NZ Ministry of Health and the remaining District Health Boards.
- Securing a contract with the Northern Territory Department of Health to extend Miya Patient Flow across Katherine Hospital in the Northern Territory.
- Hosting initial discussions with Calvary Health Care over the deployment of the Miya platform across the group, with a focus on Revenue Optimisation and Analytics and securing an initial contract to develop a Data Lake for Calvary Health Care.
- Entered into preliminary discussions with North American Strategic Partners, with a view to reciprocal distribution agreements.
- The Company’s quarterly cash and cash equivalents reduced minimally by $114k.
- Strong Cash position with Cash and cash equivalents as of 30 June 2017 of $5.531 million, with minimal debt.
- Reviewed potential acquisition targets, with the view to accelerating the Company’s commercialisation strategy through leveraging cross selling opportunities.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
